CoChat

The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index; 19 of the 61 sources its claims cite were checked for support.

3D bioprinting of high cell-density heterogeneous tissue models through spheroid fusion within self-healing hydrogels

Open access
Daly, Andrew C., Davidson, Matthew D., Burdick, Jason A. · 2021 · Nature Communications

Published version of a preprint

Abstract

Cellular models are needed to study human development and disease in vitro, and to screen drugs for toxicity and efficacy. Current approaches are limited in the engineering of functional tissue models with requisite cell densities and heterogeneity to appropriately model cell and tissue behaviors. Here, we develop a bioprinting approach to transfer spheroids into self-healing support hydrogels at high resolution, which enables their patterning and fusion into high-cell density microtissues of prescribed spatial organization. As an example application, we bioprint induced pluripotent stem cell-derived cardiac microtissue models with spatially controlled cardiomyocyte and fibroblast cell ratios to replicate the structural and functional features of scarred cardiac tissue that arise following myocardial infarction, including reduced contractility and irregular electrical activity. The bioprinted in vitro model is combined with functional readouts to probe how various pro-regenerative microRNA treatment regimes influence tissue regeneration and recovery of function as a result of cardiomyocyte proliferation. This method is useful for a range of biomedical applications, including the development of precision models to mimic diseases and the screening of drugs, particularly where high cell densities and heterogeneity are important.

Overview

CoChat Summary

TL;DR

The paper presents a 3D bioprinting method that transfers spheroids into self-healing hyaluronic acid hydrogels, enabling precise patterning and fusion into high-cell-density microtissues. It applies the method to create iPSC-derived cardiac microtissues with controlled cardiomyocyte:fibroblast ratios that model post-MI scarring and to test miR-302b/c therapeutics.

Key findings

  • Bioprinting into 3 wt% guest-host HA hydrogels achieved XY drift of ~8–15% (~15–60 µm) and Z drift of ~10–15% (~25–60 µm) of spheroid diameter; viability was ~90–95% at 3 and 5 wt% but ~87% at 7 wt%, with a per-spheroid print time of ~40 s at 400 µm/s.
  • Spheroids bioprinted in direct contact or 50 µm apart fused over 4 days; fusion index at day 0 differed between 0 and 50 µm separation (p = 0.0025), and introducing a secondary covalent network significantly reduced fusion.
  • Cardiac spheroids made at 4:1 iPSC-CMs:CFs (“healthy”) versus 1:4 (“scarred”) showed higher healthy contraction amplitude (p = 5.0 × 10−4), higher calcium transient duration (p = 0.0014) and calcium flux amplitude (p = 2.0 × 10−4), and lower time-to-peak (p = 5.0 × 10−6); scarred microtissues had increased activation delay (p = 0.0035), and two scars increased delay versus one scar (p = 0.0066).
  • miR-302b/c treatment for 4 or 7 days increased scarred spheroid contraction amplitude approximately threefold, approaching ~20% of healthy spheroid amplitudes, and increased contraction speed ~2×; it increased cTnT+EdU+ proliferation (0 vs 0–4 days p = 0.044; 0 vs 0–7 days p = 0.026) without increasing Vimentin+EdU+ cells, and reduced activation delay in scarred microtissues (p = 0.019).

Methods

  • Ad-HA/CD-HA supramolecular hydrogels were prepared at 3, 5, and 7 wt%, characterized by shear rheometry for shear-thinning and self-healing, and used as support baths for vacuum-aspiration bioprinting of spheroids via a micromanipulator and custom micropipettes.
  • hMSC spheroids (5,000 or 10,000 cells; ~200 or ~400 µm diameter) and cardiac spheroids (5,000 total iPSC-CMs plus human cardiac fibroblasts at 4:1 healthy or 1:4 scarred ratios) were formed in ultra-low attachment plates; outcomes included fusion, live/dead viability, contraction analysis with musclemotion, calcium mapping with ElectroMap, immunofluorescence, EdU proliferation, and miRNA treatment.
  • Statistical comparisons used two-tailed Student’s t tests or one-way ANOVA with Tukey post hoc testing; exact p values are reported in figure legends, with sample distribution assumed normal and equal variance.

Limitations

  • The paper states that spheroid-based microtissues lack the anisotropic tissue alignment of mature myocardium and do not include vascular networks, and that iPSC-CMs are immature, mimicking fetal rather than adult cardiomyocytes.
  • The paper notes that live cell area was used as an approximate heuristic for viability because per-cell viability was difficult to quantify in dense spheroids.
  • Evident from the text: many experiments used a single MSC donor and a single iPSC-CM donor (donor A or donor B), limiting donor diversity; some reported comparisons are trends or non-significant, such as scarred microtissue contraction amplitude (p = 0.061).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-021-21029-2

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 3D bioprinting spheroids in self-healing support hydrogels. a Schematic (top), brightfield images (middle), and fluorescent images (bottom) demonstrating, (i) MSC spheroid aspiration in a media reservoir, (ii) spheroid transfer into a self-healing support hydrogel (FITC-labeled), and (iii) spheroid deposition within the support hydrogel through removal of vacuum from the micropipette tip. Images are representative of n = 4 independent experiments. b Rheological characterization of a guest-host support hydrogel (3 wt%) demonstrating, (i) shear-thinning properties—decreased viscosity with continuously increasing shear rates (0–100 s−1) and (ii) self-healing properties—storage and loss modulus recovery (G′ & G″) through low (0.5% strain, 10 Hz) and high (shaded, 100% strain, 10 Hz) strain cycles. c Reversible interactions between guest (adamantane, blue) and host (β-cyclodextrin, orange) modified hyaluronic acid of the support hydrogel (containing FITC-microparticles) enable, (i–ii) local yielding of the support hydrogel under shear during spheroid translation, and (iii) rapid healing of the support hydrogel after spheroid translation. (iv) Displacement mapping of the support hydrogel (spheroid noted as dashed circle) demonstrating local motion of the hydrogel in front of and behind the spheroid during spheroid translation. Images are representative of n = 3 independent experiments. All scalebars 250 µm.
Fig. 1 3D bioprinting spheroids in self-healing support hydrogels. a Schematic (top), brightfield images (middle), and fluorescent images (bottom) demonstrating, (i) MSC spheroid aspiration in a media reservoir, (ii) spheroid transfer into a self-healing support hydrogel (FITC-labeled), and (iii) spheroid deposition within the support hydrogel through removal of vacuum from the micropipette tip. Images are representative of n = 4 independent experiments. b Rheological characterization of a guest-host support hydrogel (3 wt%) demonstrating, (i) shear-thinning properties—decreased viscosity with continuously increasing shear rates (0–100 s−1) and (ii) self-healing properties—storage and loss modulus recovery (G′ & G″) through low (0.5% strain, 10 Hz) and high (shaded, 100% strain, 10 Hz) strain cycles. c Reversible interactions between guest (adamantane, blue) and host (β-cyclodextrin, orange) modified hyaluronic acid of the support hydrogel (containing FITC-microparticles) enable, (i–ii) local yielding of the support hydrogel under shear during spheroid translation, and (iii) rapid healing of the support hydrogel after spheroid translation. (iv) Displacement mapping of the support hydrogel (spheroid noted as dashed circle) demonstrating local motion of the hydrogel in front of and behind the spheroid during spheroid translation. Images are representative of n = 3 independent experiments. All scalebars 250 µm.CC BY · PubMed Central
Fig. 2 Support hydrogel rheological properties and 3D bioprinting precision. a (i) Shear-yielding in guest-host support hydrogels with increasing strain (0.1–500%, 10 Hz) at varied macromer concentrations (3, 5, 7 wt%) (storage modulus G′, closed circles; loss modulus G″, open circles). (ii) Storage modulus at low strain (0.5%) at varied macromer concentrations (n = 4 hydrogel samples, mean ± s.d, one-way ANOVA, 3 vs. 5 wt% p = 1.0 × 10−5, 5 vs. 7 wt% p = 1.0 × 10−6, 3 vs. 7 wt% p = 5.0 × 10−9). (iii) Yield point (strain at G′/G″ crossover) at varied macromer concentrations (n = 4 hydrogel samples, mean ± s.d, one-way ANOVA, 3 vs. 7 wt% p = 1.0 × 10−4, 5 vs. 7 wt% p = 4.6 × 10−4). b (i) Bioprinting precision in the XY plane (XY drift %) for 200 and 400 µm diameter spheroids (n = 8, 8, 7, 7, 6, 7 biologically independent samples (from left to right), mean ± s.d, one-way ANOVA). XY drift % = post-printing spheroid drift/spheroid diameter (see Supplementary Fig. 4a i for schematic of measurement). (ii) Bioprinting precision in the Z plane (Z drift %) for 200 and 400 µm diameter spheroids (n = 9, 8, 9, 9, 7, 7 biologically independent samples (from left to right), mean ± s.d, one-way ANOVA). Z drift % = post-printing spheroid drift/spheroid diameter (see Supplementary Fig. 4a ii for schematic of measurement). c 3D bioprinted MSC spheroids within a support hydrogel (3 wt% macromer concentration) into either (i) a multi-layer cone shaped geometry (FITC-labeled spheroids) or (ii) layered rings of distinct MSC spheroid populations (FITC- or rhodamine-labeled) within the support hydrogel. All scalebars 250 µm. All experiments are from a single MSC donor. (n.s. not significant, ***p < 0.001, ****p < 0.0001).
Fig. 2 Support hydrogel rheological properties and 3D bioprinting precision. a (i) Shear-yielding in guest-host support hydrogels with increasing strain (0.1–500%, 10 Hz) at varied macromer concentrations (3, 5, 7 wt%) (storage modulus G′, closed circles; loss modulus G″, open circles). (ii) Storage modulus at low strain (0.5%) at varied macromer concentrations (n = 4 hydrogel samples, mean ± s.d, one-way ANOVA, 3 vs. 5 wt% p = 1.0 × 10−5, 5 vs. 7 wt% p = 1.0 × 10−6, 3 vs. 7 wt% p = 5.0 × 10−9). (iii) Yield point (strain at G′/G″ crossover) at varied macromer concentrations (n = 4 hydrogel samples, mean ± s.d, one-way ANOVA, 3 vs. 7 wt% p = 1.0 × 10−4, 5 vs. 7 wt% p = 4.6 × 10−4). b (i) Bioprinting precision in the XY plane (XY drift %) for 200 and 400 µm diameter spheroids (n = 8, 8, 7, 7, 6, 7 biologically independent samples (from left to right), mean ± s.d, one-way ANOVA). XY drift % = post-printing spheroid drift/spheroid diameter (see Supplementary Fig. 4a i for schematic of measurement). (ii) Bioprinting precision in the Z plane (Z drift %) for 200 and 400 µm diameter spheroids (n = 9, 8, 9, 9, 7, 7 biologically independent samples (from left to right), mean ± s.d, one-way ANOVA). Z drift % = post-printing spheroid drift/spheroid diameter (see Supplementary Fig. 4a ii for schematic of measurement). c 3D bioprinted MSC spheroids within a support hydrogel (3 wt% macromer concentration) into either (i) a multi-layer cone shaped geometry (FITC-labeled spheroids) or (ii) layered rings of distinct MSC spheroid populations (FITC- or rhodamine-labeled) within the support hydrogel. All scalebars 250 µm. All experiments are from a single MSC donor. (n.s. not significant, ***p < 0.001, ****p < 0.0001).CC BY · PubMed Central
Fig. 3 3D bioprinting microtissues through directed spheroid fusion. a (i) Schematic demonstrating the bioprinting of spheroids into rings within the support hydrogel, (ii) spheroid fusion and microtissue formation within the support hydrogel during culture, and (iii) removal of the microtissue via washing of the support hydrogel. b (i) Spheroid fusion over 4 days as a function of initial separation distance (0 or 50 µm). (ii) Fusion index (%) (see Supplementary Fig. 6a for schematic of measurement) over 4 days of culture (n = 3 biologically independent samples, mean ± s.d, one-way ANOVA, day 0 – 0 vs. 50 µm p = 0.0025). c (i–ii) Brightfield images of spheroid fusion into microtissue rings over 4 days of culture. (iii) 3D bioprinted microtissue tube composed of 3 layers of fused spheroids (after 4 days of culture and then removal from the support hydrogel). All scalebars 200 µm. All experiments are from a single MSC donor. (**p < 0.01).
Fig. 3 3D bioprinting microtissues through directed spheroid fusion. a (i) Schematic demonstrating the bioprinting of spheroids into rings within the support hydrogel, (ii) spheroid fusion and microtissue formation within the support hydrogel during culture, and (iii) removal of the microtissue via washing of the support hydrogel. b (i) Spheroid fusion over 4 days as a function of initial separation distance (0 or 50 µm). (ii) Fusion index (%) (see Supplementary Fig. 6a for schematic of measurement) over 4 days of culture (n = 3 biologically independent samples, mean ± s.d, one-way ANOVA, day 0 – 0 vs. 50 µm p = 0.0025). c (i–ii) Brightfield images of spheroid fusion into microtissue rings over 4 days of culture. (iii) 3D bioprinted microtissue tube composed of 3 layers of fused spheroids (after 4 days of culture and then removal from the support hydrogel). All scalebars 200 µm. All experiments are from a single MSC donor. (**p < 0.01).CC BY · PubMed Central
Fig. 4 Fabrication of cardiac spheroids for disease modeling applications. a (i) Development of healthy and scarred spheroids through mixing iPSC-derived cardiomyocytes (iPSC-CMs) with primary adult cardiac fibroblasts (CFs) at defined ratios of cell numbers (4:1 for healthy; 1:4 for scarred). Top: Images (cardiac troponin-T (cTnT) (red; iPSC-CMs); vimentin (green; CFs)) taken 3 days after cell seeding. Scalebar 50 µm. Bottom: Immunofluorescence staining for alpha-actinin (green; sarcomeres) and cTnT (red; iPSC-CMs) in healthy and scarred spheroids at 3 days. Scalebar 10 µm. (ii) Quantification of cellular composition through staining for cTnT (iPSC-CMs) and vimentin (CFs) (n = 3 biologically independent samples, mean ± s.d, two-sided student t test, healthy - cTnT+ vs. Vimentin+ p = 5.6 × 10−5, scarred - cTnT+ vs. Vimentin+ p = 6.7 × 10−4). b (i) Contraction profiles, (ii) contraction amplitude (a.u. absolute units), and (iii) peak-to-peak time (ms) of healthy and scarred cardiac spheroids at 3 days (n = 3 biologically independent samples, mean ± s.d, two-sided student t test, (ii) p = 5.0 × 10−4). c Quantification of calcium activation parameters from calcium mapping experiments in healthy and scarred spheroids at 3 days, including (i) calcium transient duration (ms), (ii) time-to-peak (ms), and (iii) calcium flux amplitude (F/Fo) (n = 5 biologically independent samples, mean ± s.d, two-sided student t test, (i) p = 0.0014, (ii) p = 5.0 × 10−6, (iii) p = 2.0 × 10−4). Note for n = 3 scarred spheroids a significant calcium activation peak was not observed, and these samples were not included in the statistical analysis and are denoted by x mark on the graph. All experiments are from a single iPSC-CM donor (donor A). (n.s. not significant, **p < 0.01, *** p < 0.001, **** p < 0.0001).
Fig. 4 Fabrication of cardiac spheroids for disease modeling applications. a (i) Development of healthy and scarred spheroids through mixing iPSC-derived cardiomyocytes (iPSC-CMs) with primary adult cardiac fibroblasts (CFs) at defined ratios of cell numbers (4:1 for healthy; 1:4 for scarred). Top: Images (cardiac troponin-T (cTnT) (red; iPSC-CMs); vimentin (green; CFs)) taken 3 days after cell seeding. Scalebar 50 µm. Bottom: Immunofluorescence staining for alpha-actinin (green; sarcomeres) and cTnT (red; iPSC-CMs) in healthy and scarred spheroids at 3 days. Scalebar 10 µm. (ii) Quantification of cellular composition through staining for cTnT (iPSC-CMs) and vimentin (CFs) (n = 3 biologically independent samples, mean ± s.d, two-sided student t test, healthy - cTnT+ vs. Vimentin+ p = 5.6 × 10−5, scarred - cTnT+ vs. Vimentin+ p = 6.7 × 10−4). b (i) Contraction profiles, (ii) contraction amplitude (a.u. absolute units), and (iii) peak-to-peak time (ms) of healthy and scarred cardiac spheroids at 3 days (n = 3 biologically independent samples, mean ± s.d, two-sided student t test, (ii) p = 5.0 × 10−4). c Quantification of calcium activation parameters from calcium mapping experiments in healthy and scarred spheroids at 3 days, including (i) calcium transient duration (ms), (ii) time-to-peak (ms), and (iii) calcium flux amplitude (F/Fo) (n = 5 biologically independent samples, mean ± s.d, two-sided student t test, (i) p = 0.0014, (ii) p = 5.0 × 10−6, (iii) p = 2.0 × 10−4). Note for n = 3 scarred spheroids a significant calcium activation peak was not observed, and these samples were not included in the statistical analysis and are denoted by x mark on the graph. All experiments are from a single iPSC-CM donor (donor A). (n.s. not significant, **p < 0.01, *** p < 0.001, **** p < 0.0001).CC BY · PubMed Central
Fig. 5 3D bioprinting cardiac microtissues for disease modeling applications. a (i) Schematic of 3D bioprinting of healthy and scarred cardiac microtissue rings and (ii) immunofluorescence staining for cTnT and vimentin in healthy and scarred cardiac microtissues after 5 days of fusion within the support hydrogel. Scalebar 100 µm (insets 50 µm). (iii) Immunofluorescence staining for alpha-actinin (green; sarcomeres) and cTnT (red; iPSC-CMs) and (iv) connexin-43 (green; gap junctions) and cTnT (red; iPSC-CMs), in healthy and scarred regions of microtissues after 5 days of fusion within the support hydrogel. Scalebar 10 µm. b (i) Contraction profiles of healthy and scarred cardiac microtissues following removal from the support hydrogel after 5 days of culture. (ii) Contraction amplitude (a.u. absolute units) and (iii) Peak-to-peak time (ms) at 5 days (n = 3 biologically independent samples, mean ± s.d, two-sided student t test, (ii) p = 0.061). c (i) Calcium mapping in healthy and scarred cardiac microtissues after 5 days culture, each image represents a 20 ms frame. Scalebar 100 µm. (ii) Representative calcium traces from regions 1 and 2 (see methods) in healthy and scarred cardiac microtissues. Scalebars 0.5 ΔF/Fo (y), 500 ms (x). (iii) Activation maps of healthy and scarred cardiac microtissues, and activation delay (ms) (difference in activation time (ms) between regions 1 and 2) in healthy and scarred cardiac microtissues (n = 3 biologically independent samples, mean ± s.d, two-sided student t test, p = 0.0035). d (i) Activation maps of scarred cardiac microtissues with 1 or 2 scars after 5 days of culture and (ii) quantification of activation delay (ms) (n = 3-4 biologically independent samples, mean ± s.d, two-sided student t test, p = 0.0066). e Regional quantification of (i) calcium transient duration (ms), (ii) time-to-peak (ms), and (iii) calcium flux amplitude (F/Fo), in healthy and scarred regions of microtissues (scarred 1x) after 5 days of culture (n = 4 biologically independent samples, mean ± s.d, two-sided student t test, (i) p = 0.010, (ii) p = 0.0098, (iii) p = 0.0029). Note full calcium transient duration, time-to-peak, and activation maps can be found in Supplementary Fig. 8. All experiments from a single iPSC-CM donor (donor A). (n.s. not significant, *p < 0.05, **p < 0.01).
Fig. 5 3D bioprinting cardiac microtissues for disease modeling applications. a (i) Schematic of 3D bioprinting of healthy and scarred cardiac microtissue rings and (ii) immunofluorescence staining for cTnT and vimentin in healthy and scarred cardiac microtissues after 5 days of fusion within the support hydrogel. Scalebar 100 µm (insets 50 µm). (iii) Immunofluorescence staining for alpha-actinin (green; sarcomeres) and cTnT (red; iPSC-CMs) and (iv) connexin-43 (green; gap junctions) and cTnT (red; iPSC-CMs), in healthy and scarred regions of microtissues after 5 days of fusion within the support hydrogel. Scalebar 10 µm. b (i) Contraction profiles of healthy and scarred cardiac microtissues following removal from the support hydrogel after 5 days of culture. (ii) Contraction amplitude (a.u. absolute units) and (iii) Peak-to-peak time (ms) at 5 days (n = 3 biologically independent samples, mean ± s.d, two-sided student t test, (ii) p = 0.061). c (i) Calcium mapping in healthy and scarred cardiac microtissues after 5 days culture, each image represents a 20 ms frame. Scalebar 100 µm. (ii) Representative calcium traces from regions 1 and 2 (see methods) in healthy and scarred cardiac microtissues. Scalebars 0.5 ΔF/Fo (y), 500 ms (x). (iii) Activation maps of healthy and scarred cardiac microtissues, and activation delay (ms) (difference in activation time (ms) between regions 1 and 2) in healthy and scarred cardiac microtissues (n = 3 biologically independent samples, mean ± s.d, two-sided student t test, p = 0.0035). d (i) Activation maps of scarred cardiac microtissues with 1 or 2 scars after 5 days of culture and (ii) quantification of activation delay (ms) (n = 3-4 biologically independent samples, mean ± s.d, two-sided student t test, p = 0.0066). e Regional quantification of (i) calcium transient duration (ms), (ii) time-to-peak (ms), and (iii) calcium flux amplitude (F/Fo), in healthy and scarred regions of microtissues (scarred 1x) after 5 days of culture (n = 4 biologically independent samples, mean ± s.d, two-sided student t test, (i) p = 0.010, (ii) p = 0.0098, (iii) p = 0.0029). Note full calcium transient duration, time-to-peak, and activation maps can be found in Supplementary Fig. 8. All experiments from a single iPSC-CM donor (donor A). (n.s. not significant, *p < 0.05, **p < 0.01).CC BY · PubMed Central
Fig. 6 Evaluating miRNA on the behavior of cardiac microtissues. a (i) Schematic of cholesterol modified miR302 (chol-miRNA 302 b/c) delivery to scarred cardiac spheroids for 0, 0–2, 0–4, and 0–7 days. (ii) Contraction amplitude (a.u) and (iii) peak-to-peak time (ms) within scarred spheroids measured after 2, 4, and 7 days for each treatment period (n = 4, 6, 5, 5, 7, 5, 5, 5, 5 biologically independent samples (from left to right), mean ± s.d, one-way ANOVA, (ii) day 4: 0 vs. 0–4 days treatment p = 0.014, (ii) day 7: 0 vs. 0–7 days treatment p = 0.0045, (iii) day 4: 0 vs. 0–4 days treatment p = 1.6 × 10−7, (iii) day 7: 0 vs. 0–7 days treatment p = 4.1 × 10−9). b (i) Immunofluorescence staining for cTnT (red; iPSC-CMs), vimentin (green; cardiac fibroblasts), and EdU (proliferation marker) in scarred spheroids at day 7 for each treatment condition. Top panel scalebar 50 µm, and bottom panel scalebar 40 µm. (ii) Quantification of cardiomyocyte proliferation (EdU+ and cTnT+) and (iii) fibroblast proliferation (EdU+ and Vimentin+) at day 7 for each treatment condition. (n = 3, 4, 4, 4 biologically independent samples (from left to right), mean ± s.d, one-way ANOVA, 0 vs. 0–4 days treatment p = 0.044, 0 vs. 0–7 days treatment p = 0.026). Scalebar 50 µm. c (i) Experimental outline where scarred microtissues are bioprinted in the support hydrogel as previously described, followed by 4 days treatment with miR302, and analysis compared to non-treated controls. (ii) Calcium mapping in scarred cardiac microtissues at 9 days (5 days culture in support hydrogel; (+) and (−) 4 days miRNA treatment) each frame 40 ms. Scalebar 100 µm. (iii) Representative calcium traces from regions 1 and 2 in treated and non-treated scarred cardiac microtissues. Scalebars 0.5 ΔF/Fo (y), 500 ms (x). (iv) Activation time maps across scarred regions for treated and non-treated scarred cardiac microtissues, and quantification of activation delay (ms) (n = 5 biologically independent samples, mean ± s.d, two-sided student t test, p = 0.019). d Immunofluorescence staining for cTnT (iPSC-CMs), vimentin (CFs), and EdU (proliferation) in scarred cardiac microtissues at day 9 for treated and non-treated scarred cardiac microtissues. Scalebar 50 µm. All experiments from a single iPSC-CM donor (donor B). (n.s. not significant, *p < 0.05, **p < 0.01, **** p < 0.0001).
Fig. 6 Evaluating miRNA on the behavior of cardiac microtissues. a (i) Schematic of cholesterol modified miR302 (chol-miRNA 302 b/c) delivery to scarred cardiac spheroids for 0, 0–2, 0–4, and 0–7 days. (ii) Contraction amplitude (a.u) and (iii) peak-to-peak time (ms) within scarred spheroids measured after 2, 4, and 7 days for each treatment period (n = 4, 6, 5, 5, 7, 5, 5, 5, 5 biologically independent samples (from left to right), mean ± s.d, one-way ANOVA, (ii) day 4: 0 vs. 0–4 days treatment p = 0.014, (ii) day 7: 0 vs. 0–7 days treatment p = 0.0045, (iii) day 4: 0 vs. 0–4 days treatment p = 1.6 × 10−7, (iii) day 7: 0 vs. 0–7 days treatment p = 4.1 × 10−9). b (i) Immunofluorescence staining for cTnT (red; iPSC-CMs), vimentin (green; cardiac fibroblasts), and EdU (proliferation marker) in scarred spheroids at day 7 for each treatment condition. Top panel scalebar 50 µm, and bottom panel scalebar 40 µm. (ii) Quantification of cardiomyocyte proliferation (EdU+ and cTnT+) and (iii) fibroblast proliferation (EdU+ and Vimentin+) at day 7 for each treatment condition. (n = 3, 4, 4, 4 biologically independent samples (from left to right), mean ± s.d, one-way ANOVA, 0 vs. 0–4 days treatment p = 0.044, 0 vs. 0–7 days treatment p = 0.026). Scalebar 50 µm. c (i) Experimental outline where scarred microtissues are bioprinted in the support hydrogel as previously described, followed by 4 days treatment with miR302, and analysis compared to non-treated controls. (ii) Calcium mapping in scarred cardiac microtissues at 9 days (5 days culture in support hydrogel; (+) and (−) 4 days miRNA treatment) each frame 40 ms. Scalebar 100 µm. (iii) Representative calcium traces from regions 1 and 2 in treated and non-treated scarred cardiac microtissues. Scalebars 0.5 ΔF/Fo (y), 500 ms (x). (iv) Activation time maps across scarred regions for treated and non-treated scarred cardiac microtissues, and quantification of activation delay (ms) (n = 5 biologically independent samples, mean ± s.d, two-sided student t test, p = 0.019). d Immunofluorescence staining for cTnT (iPSC-CMs), vimentin (CFs), and EdU (proliferation) in scarred cardiac microtissues at day 9 for treated and non-treated scarred cardiac microtissues. Scalebar 50 µm. All experiments from a single iPSC-CM donor (donor B). (n.s. not significant, *p < 0.05, **p < 0.01, **** p < 0.0001).CC BY · PubMed Central

Verification

Claims the paper makes

9 Valid · 2 Not valid · 21 Not checked · 93 Own results and interpretations

47 more claims

Create a free account to see all 125 claims and to verify the 42 references still open.

See all claims — free account
  • Probably not a substantial claim. 27
  • It may state two separate claims as one. 53
  • The quote only partly states this claim. 4

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 76 references

Cited by

See all 476

Metadata

Authors
Daly, A. C., Davidson, M. D., & Burdick, J. A.
Affiliations
University of Pennsylvania (US)
Corresponding author
Burdick, Jason A.
Venue
Nature Communications
Published
2021-02-02
Volume
12
Issue
1
Pages
753-753
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3126743042
Cited by
470
References
76
Citations by year
2026: 53 · 2025: 87 · 2024: 94 · 2023: 92 · 2022: 83 · 2021: 60
FWCI
24.96
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • American Heart Association (20POST35210923)
  • U.S. Department of Health & Human Services | National Institutes of Health (F32 DK117568, R01HL137365, R01HL135090)
  • National Science Foundation (CMMI: 15-48571)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
  • Physical Sciences › Materials Science › Biomaterials › Hydrogels: synthesis, properties, applications
Keywords
3D bioprinting, spheroid fusion, self-healing hydrogels, high cell density, iPSC-derived cardiomyocytes, cardiac microtissues, myocardial infarction, microRNA, cardiomyocyte proliferation, tissue regeneration, drug screening, disease modeling
MeSH terms
Biomedical Engineering, Cardiovascular Diseases, Drug Evaluation, Preclinical, Drug Delivery Systems, Spheroids, Cellular, Hydrogels, Tissue Engineering, Pluripotent Stem Cells, Bioprinting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 3D bioprinting of high cell-density heterogeneous tissue models through spheroid fusion within self-healing hydrogels. https://app.cochat.ai/papers/10.1038/s41467-021-21029-2
The paper
Daly, A. C., Davidson, M. D., & Burdick, J. A. (2021). 3D bioprinting of high cell-density heterogeneous tissue models through spheroid fusion within self-healing hydrogels. Nature Communications. https://doi.org/10.1038/s41467-021-21029-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.